Short Interest in Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Declines By 71.4%

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) saw a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 1,200 shares, a drop of 71.4% from the December 15th total of 4,200 shares. Based on an average daily volume of 11,400 shares, the days-to-cover ratio is currently 0.1 days.

Scinai Immunotherapeutics Stock Up 0.6 %

Shares of Scinai Immunotherapeutics stock traded up $0.02 during midday trading on Tuesday, hitting $3.44. The company’s stock had a trading volume of 2,964 shares, compared to its average volume of 10,908. The firm has a market capitalization of $2.93 million, a P/E ratio of -0.01 and a beta of 2.34. The stock has a 50-day simple moving average of $3.34 and a 200-day simple moving average of $3.61. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.06. Scinai Immunotherapeutics has a 1-year low of $2.23 and a 1-year high of $8.92.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.